Clinical Trial

A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-03-24; most recent amendment 2026-04-07.
Status change: Recruiting → Active, Not Recruiting 2025-11-12
Trial Details
NCT Number NCT06903338
Lead Sponsor Vir Biotechnology, Inc.
Conditions Viral Hepatitis
Enrollment 124 participants
Start Date 2025-03-12
Primary Completion 2026-12-31 (estimated)
Study Completion 2031-05 (estimated)
Updated on ClinicalTrials.gov 2026-04-08